346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

by Christian Poehlein, Joseph Burgents, Christian Gratzke, Cuizhen Niu
Published 2020-11-01

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)

by Arnulf Stenzl, Julie Nicole Graff, Joseph Burgents, Li Wen Liang
Published 2020-11-01